Oxford Nanopore Technologies plc (ONT) Fair Value & Analysis
Healthcare · GB · Market cap 1.3B GBX
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price −14.6% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.9801 – £2.05 · fair‑value band £1.61 – £2.68 · the £1.15 price screens below the £2.14 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Oxford Nanopore Technologies plc (ONT) currently trades at £1.15, while our model-based Fair Value estimate is £2.14 — implying the stock looks roughly 86.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Oxford Nanopore Technologies plc generated revenue of £224M at a net margin of -64.9%. Revenue grew 19.4% year over year. It earns a return on equity of -27.7%. The balance sheet holds a net cash position of £140M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions. It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Oxford Nanopore Technologies plc reported revenue of £224M in FY2025 versus £134M in FY2021, a compound +13.8%/yr. Reported net income was −£145M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Oxford Nanopore Technologies plc (ONT) undervalued?
What is the fair value of ONT?
What is the quality score of ONT?
What is the revenue of Oxford Nanopore Technologies plc (ONT)?
What is the net profit margin of ONT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.